Workflow #3590
✓ CompletedType: Benzinga Article
Started: December 05, 2025 at 9:27:01 PM
Completed: December 05, 2025 at 9:27:03 PM
Completed in 1s
Triggered by: ingestion
Job Pipeline
clean_raw_article
✓ completed→
clean_markdown_article
✓ completed→
analyze_article
✓ completed→
link_article_to_stories
⊘ skipped→
analyze_sentiment
✓ completedclean_raw_article
✓ CompletedPending
clean_markdown_article
✓ CompletedPending
analyze_article
✓ CompletedPending
link_article_to_stories
⊘ SkippedSkipped
analyze_sentiment
✓ CompletedPending
Workflow Context
content:
article_id:5212 →
content_type:article
title:On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
source:Benzinga